Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
about
Influence of Immune Myeloid Cells on the Extracellular Matrix During Cancer MetastasisMembrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substratesTargeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in miceCancer associated fibroblasts (CAFs) in tumor microenvironment.Endogenous Myc maintains the tumor microenvironment.Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient miceMmp1a and Mmp1b are not functional orthologs to human MMP1 in cigarette smoke induced lung diseaseDetection of enzyme activity in orthotopic murine breast cancer by fluorescence lifetime imaging using a fluorescence resonance energy transfer-based molecular probeFinding cancer's weakest link.Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter.Reversal of aberrant cancer methylome and transcriptome upon direct reprogramming of lung cancer cellsTowards third generation matrix metalloproteinase inhibitors for cancer therapyCathepsin B inhibition limits bone metastasis in breast cancer.Matrix metalloproteases: underutilized targets for drug deliveryExpression and localization of matrix metalloproteinases (MMP-2, -7, -9) and their tissue inhibitors (TIMP-2, -3) in the chicken oviduct during maturationMechanical Characterization of a Dynamic and Tunable Methacrylated Hyaluronic Acid Hydrogel.MMPs as therapeutic targets--still a viable option?Inhibition of angiogenesis and invasion in malignant gliomas.Metalloproteases as potential therapeutic targets in arthritis treatment.Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus.Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.In vitro evaluation of functional interaction of integrin alphavbeta3 and matrix metalloprotease-2.Matrix metalloproteinase pharmacogenomics in non-small-cell lung carcinoma.Optical imaging in cancer research: basic principles, tumor detection, and therapeutic monitoring.Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.The canonical methionine 392 of matrix metalloproteinase 2 (gelatinase A) is not required for catalytic efficiency or structural integrity: probing the role of the methionine-turn in the metzincin metalloprotease superfamily.The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.Modes of invasion during tumour dissemination.New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment.Pivotal molecular determinants of peptidic and collagen triple helicase activities reside in the S3' subsite of matrix metalloproteinase 8 (MMP-8): the role of hydrogen bonding potential of ASN188 and TYR189 and the connecting cis bond.Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging.
P2860
Q26767150-A015C08A-EFFF-4595-969A-460C693B200DQ33202468-50199573-995F-4A2C-96B1-5015A1EC6726Q33696289-116EDF4B-373E-4174-94E9-8DA0F6B75898Q33999773-B3CD7CE9-CC7D-4E36-908B-71B22C748B09Q34177033-1E60AF1F-EF4F-4EA3-8C08-1269E0FB9F59Q34236802-B4EAEC21-F1FB-45F2-B4AB-7A260BD24A57Q35019702-6D4E3BE2-0D5B-4973-B90C-9AAF488F80A8Q35112547-BBAF0CBA-B506-4EA5-9624-9161414D7473Q35764388-8AE1813C-648A-4222-AC5A-CB0BF7191D54Q35929334-58D862A7-B88E-40F5-A22C-A29162CECCD2Q36177485-B3BB232B-FA7D-4A0F-99E4-42EFEEA94D56Q36421691-D7E3AA02-BD56-41FD-8FFB-EE680BB5ABACQ36511851-E8A3ADFC-09AD-4FED-9978-EF17DAFA49D3Q36761849-5FD75002-6DA6-470F-93A7-00EBFEDD241EQ36762296-907F4403-CE82-49B2-BA9A-B9475DCA0003Q36833080-55D72360-C315-4B6A-9B08-D1EF7E05A763Q36908023-AB850072-8B13-45BE-B413-1DFEBB669DC7Q37004664-F9A25A22-3CE4-4A48-8ECD-D4EF0AB9719DQ37030862-87E1D8EA-5017-420C-A482-F23868A3B0FDQ37311960-D7FBDDA7-4A31-4F52-AF37-2C381142E597Q37461337-43271E7D-EE9D-4B17-B2E4-27482F2F62F2Q37467465-13AF3E01-5ADB-41B9-AB12-8174721FC849Q37869122-0A99BE91-75F6-4926-91E3-4A1A59F7A6A3Q37901290-F398CD7E-FCAE-4E0E-B797-CBFECF44A779Q37948053-2774532E-3562-485E-98B6-C5CC5509F119Q38345793-DFC75330-2752-47FC-88F7-92EDE6931E68Q38881849-B5CFCAA7-8D34-435F-A4FE-E8BA66B5887DQ39085737-AA29F760-1731-4834-B1E6-6374794A9B47Q42239363-C78ADA92-98B9-4022-9C95-029A7E23D42CQ45144490-C68E037F-53E1-488A-8930-9385057C6D4FQ47394596-7596C6BD-EB83-4A32-AA6C-4A039E3E4BF0Q53301416-2B600537-6E76-43BD-A877-DD060BB6B408
P2860
Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Matrix metalloproteinase inhib ...... ituation and future prospects.
@ast
Matrix metalloproteinase inhib ...... ituation and future prospects.
@en
type
label
Matrix metalloproteinase inhib ...... ituation and future prospects.
@ast
Matrix metalloproteinase inhib ...... ituation and future prospects.
@en
prefLabel
Matrix metalloproteinase inhib ...... ituation and future prospects.
@ast
Matrix metalloproteinase inhib ...... ituation and future prospects.
@en
P2860
P356
P1476
Matrix metalloproteinase inhib ...... ituation and future prospects.
@en
P2093
Barbara Fingleton
P2860
P304
P356
10.1517/14728222.7.3.385
P407
P577
2003-06-01T00:00:00Z